Prevalence, Distribution, and Impact of Mild Cognitive Impairment in Latin America, China, and India: A 10/66 Population-Based Study

National Institute of Neurology and Neurosurgery, Autonomous National University of Mexico, Mexico City, Mexico.
PLoS Medicine (Impact Factor: 14.43). 02/2012; 9(2):e1001170. DOI: 10.1371/journal.pmed.1001170
Source: PubMed


Rapid demographic ageing is a growing public health issue in many low- and middle-income countries (LAMICs). Mild cognitive impairment (MCI) is a construct frequently used to define groups of people who may be at risk of developing dementia, crucial for targeting preventative interventions. However, little is known about the prevalence or impact of MCI in LAMIC settings.
Data were analysed from cross-sectional surveys established by the 10/66 Dementia Research Group and carried out in Cuba, Dominican Republic, Peru, Mexico, Venezuela, Puerto Rico, China, and India on 15,376 individuals aged 65+ without dementia. Standardised assessments of mental and physical health, and cognitive function were carried out including informant interviews. An algorithm was developed to define Mayo Clinic amnestic MCI (aMCI). Disability (12-item World Health Organization disability assessment schedule [WHODAS]) and informant-reported neuropsychiatric symptoms (neuropsychiatric inventory [NPI-Q]) were measured. After adjustment, aMCI was associated with disability, anxiety, apathy, and irritability (but not depression); between-country heterogeneity in these associations was only significant for disability. The crude prevalence of aMCI ranged from 0.8% in China to 4.3% in India. Country differences changed little (range 0.6%-4.6%) after standardization for age, gender, and education level. In pooled estimates, aMCI was modestly associated with male gender and fewer assets but was not associated with age or education. There was no significant between-country variation in these demographic associations.
An algorithm-derived diagnosis of aMCI showed few sociodemographic associations but was consistently associated with higher disability and neuropsychiatric symptoms in addition to showing substantial variation in prevalence across LAMIC populations. Longitudinal data are needed to confirm findings-in particular, to investigate the predictive validity of aMCI in these settings and risk/protective factors for progression to dementia; however, the large number affected has important implications in these rapidly ageing settings.

Download full-text


Available from: Aquiles Salas,
1 Follower
35 Reads
  • Source
    • "The World Health Organization Disability Assessment Schedule 2.0 (WHO DAS) is a 12-item questionnaire that serves as a crosscultural measure of functional status in six domains: cognition, mobility, self-care, social interaction, life activities, and participation in the community. This instrument is broadly useful for measuring functional impairment from acute and chronic illnesses, physical disabilities, cognitive disorders, and mental illness (Sosa et al., 2012). It has been validated in 19 countries, including three sites in India. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In India, “non-notified” slums are not officially recognized by city governments; they suffer from insecure tenure and poorer access to basic services than “notified” (government-recognized) slums. We conducted a study in a non-notified slum of about 12,000 people in Mumbai to determine the prevalence of individuals at high risk for having a common mental disorder (i.e., depression and anxiety), to ascertain the impact of mental health on the burden of functional impairment, and to assess the influence of the slum environment on mental health. We gathered qualitative data (six focus group discussions and 40 individual interviews in July-November 2011), with purposively sampled participants, and quantitative data (521 structured surveys in February 2012), with respondents selected using community-level random sampling. For the surveys, we administered the General Health Questionnaire-12 (GHQ) to screen for common mental disorders (CMDs), the WHO Disability Assessment Schedule 2.0 (WHO DAS) to screen for functional impairment, and a slum adversity questionnaire, which we used to create a composite Slum Adversity Index (SAI) score. Twenty-three percent of individuals have a GHQ score ≥5, suggesting they are at high risk for having a CMD. Psychological distress is a major contributor to the slum’s overall burden of functional impairment. In a multivariable logistic regression model, household income, poverty-related factors, and the SAI score all have strong independent associations with CMD risk. The qualitative findings suggest that non-notified status plays a central role in creating psychological distress—by creating and exacerbating deprivations that serve as sources of stress, by placing slum residents in an inherently antagonistic relationship with the government through the criminalization of basic needs, and by shaping a community identity built on a feeling of social exclusion from the rest of the city.
    Social Science & Medicine 10/2014; 119:155-169. DOI:10.1016/j.socscimed.2014.08.021 · 2.89 Impact Factor
  • Source
    • "Furthermore, the diagnostic subtypes in these two studies were loosely defined, relied substantially on clinical judgment, and lacked the support of brain imaging findings, which are necessary for an etiological diagnosis [10] [11]. Few surveys on MCI have been conducted in China [12] [13] [14] [15] [16] [17]. Furthermore, most of these studies were regional and recruited only individuals from urban populations. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Epidemiologic studies on mild cognitive impairment (MCI) are limited in China. Using a multistage cluster sampling design, a total of 10,276 community residents (6096 urban, 4180 rural) aged 65 years or older were evaluated and diagnosed with normal cognition, MCI, or dementia. MCI was further categorized by imaging into MCI caused by prodromal Alzheimer's disease (MCI-A), MCI resulting from cerebrovascular disease (MCI-CVD), MCI with vascular risk factors (MCI-VRF), and MCI caused by other diseases (MCI-O). The prevalences of overall MCI, MCI-A, MCI-CVD, MCI-VRF, and MCI-O were 20.8% (95% confidence interval [CI] = 20.0-21.6%), 6.1% (95% CI = 5.7-6.6%), 3.8% (95% CI = 3.4-4.2%), 4.9% (95% CI = 4.5-5.4%), and 5.9% (95% CI = 5.5-6.4%) respectively. The rural population had a higher prevalence of overall MCI (23.4% vs 16.8%, P < .001). The prevalence of MCI in elderly Chinese is higher in rural than in urban areas. Vascular-related MCI (MCI-CVD and MCI-VRF) was most common.
    Alzheimer's & dementia: the journal of the Alzheimer's Association 01/2014; 10(4). DOI:10.1016/j.jalz.2013.09.008 · 12.41 Impact Factor
  • Source
    • "Considering that 58% of all people with dementia worldwide live in lowand middle-income countries, increasing to 71% by 2050 [5], and the different social, environmental, and health care characteristics of these communities with respect to those in high-income countries, there is a critical research gap to be urgently filled. The results obtained through the 10/66 Dementia Research Group are encouraging, but much more efforts are needed [21] [22]; b) As far as biomarkers are concerned, the majority (37/62) are using neuroimaging, and less (18/62) are collecting CSF for peptides determination. Few others are looking for peripheral biomarkers (plasma, lymphocytes ); c) Omics determinations are mainly focused on DNA and/or RNA (21/62) and ApoE genotyping (15/62); transcriptomics and metabolomics are exceptions ; d) The majority of studies are supported by public funding, although the private sector is contributing to the ADNIs [14] and few other studies. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study describes the main characteristics of ongoing observational studies on Alzheimer's disease (AD) to help identify any important research gaps. A search through the WHO International Clinical Trials Registry Platform and on the Primary Registries was conducted on 9 June 2012. The descriptors 'recruiting' or 'open' were used to describe a study's recruitment status. 62 studies are being conducted in 18 countries (Australia, Far-East, Middle-East, North America, and Western Europe). The US and France are involved in 55% of these studies. The studies aimed to recruit 20 to 10,000 participants, lasting 8 months to 24 years; 46% are case-control, whereas 44% are cohort studies; 60% and 34% are longitudinal and cross-sectional, respectively. The majority are sponsored by hospitals, universities, medical centers, or public health systems (63%), and are conducted in single centers (55%). 37 use imaging (MRI, PET, SPECT), 18 conduct lumbar puncture, 21 collect DNA and/or RNA, and 15 collect ApoE genotyping. 17 studies are medium-term prospective disease progression studies, the majority to assess mild cognitive impairment (MCI) or/and AD progression; only 3 are on cognitively normal older people at risk (2 studies, n = 180) or not (1 study, n < 200) of developing MCI. Observational studies are being conducted in few countries, with very few in low and middle-income countries where the majority of AD patients live. There is a remarkable interest in disease progression studies; however, longitudinal, long-term studies, on cognitively normal middle-age individuals, of key importance to try to fully understand the preclinical phase of AD, are lacking.
    Journal of Alzheimer's disease: JAD 11/2012; 34(1). DOI:10.3233/JAD-121525 · 4.15 Impact Factor
Show more